152 related articles for article (PubMed ID: 30326146)
1. Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.
Wang L; Rambau PF; Kelemen LE; Anglesio MS; Leung S; Talhouk A; Köbel M
Histopathology; 2019 Feb; 74(3):452-462. PubMed ID: 30326146
[TBL] [Abstract][Full Text] [Related]
2. Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary.
Rosen DG; Zhang Z; Chang B; Wang X; Lin E; Liu J
Mod Pathol; 2010 Jan; 23(1):113-22. PubMed ID: 19820688
[TBL] [Abstract][Full Text] [Related]
3. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
[TBL] [Abstract][Full Text] [Related]
4. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract][Full Text] [Related]
5. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2.
Houghton O; Connolly LE; McCluggage WG
Histopathology; 2008 Aug; 53(2):156-65. PubMed ID: 18752499
[TBL] [Abstract][Full Text] [Related]
6. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
[TBL] [Abstract][Full Text] [Related]
7. A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma.
Le Page C; Köbel M; Meunier L; Provencher DM; Mes-Masson AM; Rahimi K
J Pathol Clin Res; 2019 Jul; 5(3):177-188. PubMed ID: 30924313
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
Yoneoka Y; Yoshida H; Ishikawa M; Shimizu H; Uehara T; Murakami T; Kato T
J Gynecol Oncol; 2019 Jan; 30(1):e7. PubMed ID: 30479091
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Dickkopf-1 and ß-catenin expression in advanced gastric cancer.
Hong SA; Yoo SH; Lee HH; Sun S; Won HS; Kim O; Ko YH
BMC Cancer; 2018 May; 18(1):506. PubMed ID: 29720122
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
[TBL] [Abstract][Full Text] [Related]
13. beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.
Gamallo C; Palacios J; Moreno G; Calvo de Mora J; Suárez A; Armas A
Am J Pathol; 1999 Aug; 155(2):527-36. PubMed ID: 10433945
[TBL] [Abstract][Full Text] [Related]
14. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
[TBL] [Abstract][Full Text] [Related]
15. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
Soovares P; Pasanen A; Similä-Maarala J; Bützow R; Lassus H
Gynecol Oncol; 2022 Jan; 164(1):187-194. PubMed ID: 34711431
[TBL] [Abstract][Full Text] [Related]
17. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer.
Bodnar L; Stanczak A; Cierniak S; Smoter M; Cichowicz M; Kozlowski W; Szczylik C; Wieczorek M; Lamparska-Przybysz M
J Ovarian Res; 2014 Feb; 7():16. PubMed ID: 24499657
[TBL] [Abstract][Full Text] [Related]
18. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
19. Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles.
Kelemen LE; Rambau PF; Koziak JM; Steed H; Köbel M
Cancer Causes Control; 2017 May; 28(5):447-457. PubMed ID: 28194593
[TBL] [Abstract][Full Text] [Related]
20. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
